Global and Regional Hepatitis Drugs
Global and Regional Hepatitis Drugs

Hepatitis Drugs Comprehensive Study by Type (Interferon Alphas, Monoclonal Antibody, Nucleotide Polymerase/NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors, Others), Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, Others), Route of Administration (Oral, Injection), End-User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Players and Region - Global Market Outlook to 2027

Hepatitis Drugs Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

Apr 2022 Edition 218 Pages 224 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Hepatitis Drugs Market Scope
Hepatitis B is a virus that attacks the liver and causes acute and chronic liver disease. According to the World Health Organization (WHO), around 780,000 individuals die each year as a result of hepatitis B complications such as liver cirrhosis and cancer. Hepatitis B virus (HBV) is highly contagious and is spread by contact with an infected person's blood or other bodily fluids. Infection A, infection B, infection C, infection D, infection E, and infection G are some of the infections that cause hepatitis. The illness causes inflammation of the liver tissues, which can lead to cirrhosis and cancer.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledF. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Vertex Pharmaceuticals, Abbvie, Achillion Pharmaceuticals, Bristol-Myers SquibbMerck & Co. Inc. (United States), Gilead Sciences Inc. (United States), AbbVie Inc. (United States), Bristol Myers Squibb Company (United States), F. Hoffmann-La Roche Ltd. (Switzerland), LAURUS Labs (India), Zydus Cadila (India), Hetero Healthcare Limited (India), GlaxoSmithKline PLC. (United Kingdom) and Cipla Inc. (India)
CAGR%


The Hepatitis Therapeutics Market is competitive and fragmented, with several prominent companies. However, in terms of market share, the market is now dominated by a few significant competitors. Merck & Co., Inc, Gilead Sciences, Inc, AbbVie Inc, Bristol Myers Squibb Company, F. Hoffmann-La Roche, Ltd, LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, NATCO Pharma Limited, and Cipla Inc are some of the top market players.

F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Vertex Pharmaceuticals, Abbvie, Achillion Pharmaceuticals, Bristol-Myers SquibbMerck & Co. Inc. (United States), Gilead Sciences Inc. (United States), AbbVie Inc. (United States), Bristol Myers Squibb Company (United States), F. Hoffmann-La Roche Ltd. (Switzerland), LAURUS Labs (India), Zydus Cadila (India), Hetero Healthcare Limited (India), GlaxoSmithKline PLC. (United Kingdom) and Cipla Inc. (India) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
The study have segmented the market of Global Hepatitis Drugs market by Type (Interferon Alphas, Monoclonal Antibody, Nucleotide Polymerase/NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Others) and Region with country level break-up.

On the basis of application, segment is dominating the market in the year 2021

On the basis of geography, the market of Hepatitis Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2021.

In 2022, the only 3-antigen HBV vaccination for adults in the United States, PreHevbrio for hepatitis B, was approved by the United States Food and Drug Administration. and In 2021, The Malaysian National Pharmaceutical Regulatory Agency (NPRA) granted conditional registration to a safe and effective hepatitis C treatment developed by a public-private partnership involving the Malaysian Ministry of Health, the Drugs for Neglected Diseases Initiative (DNDi), Egyptian pharmaceutical company Pharco, Pharmaniaga Berhad, and Médecins Sans Frontières/Doctors Without Borders (MSF).


Market Trend
  • Growing Technological Advancements in the Healthcare Industry

Market Drivers
  • The Global Hepatitis Drug Market Is Predicted to rise Due To an Increase in New Drug Releases and Regulatory Approvals for Hepatitis Drugs
  • Increasing Geriatric Population
  • Efficiency in Drug Treatment of Hepatitis C Drives the Market Growth

Opportunities
  • Increasing Drug Manufacture in the Developing Country
  • Adoption of New Advanced Technology in the Market

Restraints
  • High Capital Requirement for Manufacturing Hepatitis Drugs
  • Costly Manufacture Process and Expensive Raw Materials

Challenges
  • Increasing Government Regulation in Market
  • High Costs Associated With Drug


Key Target Audience
Industry Association, Downstream Vendors, Marketing & Consulting firms, Venture Capitalists, Government & Regulatory Bodies and Investors

Frequently Asked Questions (FAQ):

1. What are the key segments playing vital role in Hepatitis Drugs Market?
The Hepatitis Drugs study can be customized to meet your requirements. The market size breakdown by type [Interferon Alphas, Monoclonal Antibody, Nucleotide Polymerase/NS5A Inhibitor Combinations, HIV NRTIs, NS5A Inhibitors, Nucleotide Polymerase Inhibitors and Others], by end use application [].

2. How big is the Hepatitis Drugs Market?
The Hepatitis Drugs Market is gaining popularity and expected to see strong valuation by 2027.

Report Objectives / Segmentation Covered
By Type
  • Interferon Alphas
  • Monoclonal Antibody
  • Nucleotide Polymerase/NS5A Inhibitor Combinations
  • HIV NRTIs
  • NS5A Inhibitors
  • Nucleotide Polymerase Inhibitors
  • Others
By Disease Type
  • Hepatitis A
  • Hepatitis B
  • Hepatitis C
  • Others

By Route of Administration
  • Oral
  • Injection

By End-User
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Global Hepatitis Drug Market Is Predicted to rise Due To an Increase in New Drug Releases and Regulatory Approvals for Hepatitis Drugs
      • 3.2.2. Increasing Geriatric Population
      • 3.2.3. Efficiency in Drug Treatment of Hepatitis C Drives the Market Growth
    • 3.3. Market Challenges
      • 3.3.1. Increasing Government Regulation in Market
      • 3.3.2. High Costs Associated With Drug
    • 3.4. Market Trends
      • 3.4.1. Growing Technological Advancements in the Healthcare Industry
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hepatitis Drugs, by Type, Disease Type, Route of Administration, End-User and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Hepatitis Drugs (Value)
      • 5.2.1. Global Hepatitis Drugs by: Type (Value)
        • 5.2.1.1. Interferon Alphas
        • 5.2.1.2. Monoclonal Antibody
        • 5.2.1.3. Nucleotide Polymerase/NS5A Inhibitor Combinations
        • 5.2.1.4. HIV NRTIs
        • 5.2.1.5. NS5A Inhibitors
        • 5.2.1.6. Nucleotide Polymerase Inhibitors
        • 5.2.1.7. Others
      • 5.2.2. Global Hepatitis Drugs by: Disease Type (Value)
        • 5.2.2.1. Hepatitis A
        • 5.2.2.2. Hepatitis B
        • 5.2.2.3. Hepatitis C
        • 5.2.2.4. Others
      • 5.2.3. Global Hepatitis Drugs by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Injection
      • 5.2.4. Global Hepatitis Drugs by: End-User (Value)
        • 5.2.4.1. Hospital Pharmacies
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Online Pharmacies
      • 5.2.5. Global Hepatitis Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Hepatitis Drugs (Price)
      • 5.3.1. Global Hepatitis Drugs by: Type (Price)
  • 6. Hepatitis Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. F. Hoffmann-La Roche
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Gilead Sciences
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Johnson & Johnson
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Vertex Pharmaceuticals
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Abbvie
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Achillion Pharmaceuticals
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bristol-Myers SquibbMerck & Co. Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Gilead Sciences Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. AbbVie Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Bristol Myers Squibb Company (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. LAURUS Labs (India)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Zydus Cadila (India)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
      • 6.4.17. Hetero Healthcare Limited (India)
        • 6.4.17.1. Business Overview
        • 6.4.17.2. Products/Services Offerings
        • 6.4.17.3. Financial Analysis
        • 6.4.17.4. SWOT Analysis
      • 6.4.18. GlaxoSmithKline PLC. (United Kingdom)
        • 6.4.18.1. Business Overview
        • 6.4.18.2. Products/Services Offerings
        • 6.4.18.3. Financial Analysis
        • 6.4.18.4. SWOT Analysis
      • 6.4.19. Cipla Inc. (India)
        • 6.4.19.1. Business Overview
        • 6.4.19.2. Products/Services Offerings
        • 6.4.19.3. Financial Analysis
        • 6.4.19.4. SWOT Analysis
  • 7. Global Hepatitis Drugs Sale, by Type, Disease Type, Route of Administration, End-User and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Hepatitis Drugs (Value)
      • 7.2.1. Global Hepatitis Drugs by: Type (Value)
        • 7.2.1.1. Interferon Alphas
        • 7.2.1.2. Monoclonal Antibody
        • 7.2.1.3. Nucleotide Polymerase/NS5A Inhibitor Combinations
        • 7.2.1.4. HIV NRTIs
        • 7.2.1.5. NS5A Inhibitors
        • 7.2.1.6. Nucleotide Polymerase Inhibitors
        • 7.2.1.7. Others
      • 7.2.2. Global Hepatitis Drugs by: Disease Type (Value)
        • 7.2.2.1. Hepatitis A
        • 7.2.2.2. Hepatitis B
        • 7.2.2.3. Hepatitis C
        • 7.2.2.4. Others
      • 7.2.3. Global Hepatitis Drugs by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Injection
      • 7.2.4. Global Hepatitis Drugs by: End-User (Value)
        • 7.2.4.1. Hospital Pharmacies
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Online Pharmacies
      • 7.2.5. Global Hepatitis Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Hepatitis Drugs (Price)
      • 7.3.1. Global Hepatitis Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hepatitis Drugs: by Type(USD Million)
  • Table 2. Hepatitis Drugs Interferon Alphas , by Region USD Million (2016-2021)
  • Table 3. Hepatitis Drugs Monoclonal Antibody , by Region USD Million (2016-2021)
  • Table 4. Hepatitis Drugs Nucleotide Polymerase/NS5A Inhibitor Combinations , by Region USD Million (2016-2021)
  • Table 5. Hepatitis Drugs HIV NRTIs , by Region USD Million (2016-2021)
  • Table 6. Hepatitis Drugs NS5A Inhibitors , by Region USD Million (2016-2021)
  • Table 7. Hepatitis Drugs Nucleotide Polymerase Inhibitors , by Region USD Million (2016-2021)
  • Table 8. Hepatitis Drugs Others , by Region USD Million (2016-2021)
  • Table 9. Hepatitis Drugs: by Disease Type(USD Million)
  • Table 10. Hepatitis Drugs Hepatitis A , by Region USD Million (2016-2021)
  • Table 11. Hepatitis Drugs Hepatitis B , by Region USD Million (2016-2021)
  • Table 12. Hepatitis Drugs Hepatitis C , by Region USD Million (2016-2021)
  • Table 13. Hepatitis Drugs Others , by Region USD Million (2016-2021)
  • Table 14. Hepatitis Drugs: by Route of Administration(USD Million)
  • Table 15. Hepatitis Drugs Oral , by Region USD Million (2016-2021)
  • Table 16. Hepatitis Drugs Injection , by Region USD Million (2016-2021)
  • Table 17. Hepatitis Drugs: by End-User(USD Million)
  • Table 18. Hepatitis Drugs Hospital Pharmacies , by Region USD Million (2016-2021)
  • Table 19. Hepatitis Drugs Retail Pharmacies , by Region USD Million (2016-2021)
  • Table 20. Hepatitis Drugs Online Pharmacies , by Region USD Million (2016-2021)
  • Table 21. South America Hepatitis Drugs, by Country USD Million (2016-2021)
  • Table 22. South America Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 23. South America Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 24. South America Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 25. South America Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 26. Brazil Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 27. Brazil Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 28. Brazil Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 29. Brazil Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 30. Argentina Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 31. Argentina Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 32. Argentina Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 33. Argentina Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 34. Rest of South America Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 35. Rest of South America Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 36. Rest of South America Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 37. Rest of South America Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 38. Asia Pacific Hepatitis Drugs, by Country USD Million (2016-2021)
  • Table 39. Asia Pacific Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 40. Asia Pacific Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 41. Asia Pacific Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 42. Asia Pacific Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 43. China Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 44. China Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 45. China Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 46. China Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 47. Japan Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 48. Japan Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 49. Japan Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 50. Japan Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 51. India Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 52. India Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 53. India Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 54. India Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 55. South Korea Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 56. South Korea Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 57. South Korea Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 58. South Korea Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 59. Taiwan Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 60. Taiwan Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 61. Taiwan Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 62. Taiwan Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 63. Australia Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 64. Australia Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 65. Australia Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 66. Australia Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 67. Rest of Asia-Pacific Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 68. Rest of Asia-Pacific Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 69. Rest of Asia-Pacific Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 70. Rest of Asia-Pacific Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 71. Europe Hepatitis Drugs, by Country USD Million (2016-2021)
  • Table 72. Europe Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 73. Europe Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 74. Europe Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 75. Europe Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 76. Germany Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 77. Germany Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 78. Germany Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 79. Germany Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 80. France Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 81. France Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 82. France Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 83. France Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 84. Italy Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 85. Italy Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 86. Italy Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 87. Italy Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 88. United Kingdom Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 89. United Kingdom Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 90. United Kingdom Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 91. United Kingdom Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 92. Netherlands Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 93. Netherlands Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 94. Netherlands Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 95. Netherlands Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 96. Rest of Europe Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 97. Rest of Europe Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 98. Rest of Europe Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 99. Rest of Europe Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 100. MEA Hepatitis Drugs, by Country USD Million (2016-2021)
  • Table 101. MEA Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 102. MEA Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 103. MEA Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 104. MEA Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 105. Middle East Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 106. Middle East Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 107. Middle East Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 108. Middle East Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 109. Africa Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 110. Africa Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 111. Africa Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 112. Africa Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 113. North America Hepatitis Drugs, by Country USD Million (2016-2021)
  • Table 114. North America Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 115. North America Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 116. North America Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 117. North America Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 118. United States Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 119. United States Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 120. United States Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 121. United States Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 122. Canada Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 123. Canada Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 124. Canada Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 125. Canada Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 126. Mexico Hepatitis Drugs, by Type USD Million (2016-2021)
  • Table 127. Mexico Hepatitis Drugs, by Disease Type USD Million (2016-2021)
  • Table 128. Mexico Hepatitis Drugs, by Route of Administration USD Million (2016-2021)
  • Table 129. Mexico Hepatitis Drugs, by End-User USD Million (2016-2021)
  • Table 130. Hepatitis Drugs: by Type(USD/Units)
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Company Basic Information, Sales Area and Its Competitors
  • Table 147. Company Basic Information, Sales Area and Its Competitors
  • Table 148. Company Basic Information, Sales Area and Its Competitors
  • Table 149. Company Basic Information, Sales Area and Its Competitors
  • Table 150. Hepatitis Drugs: by Type(USD Million)
  • Table 151. Hepatitis Drugs Interferon Alphas , by Region USD Million (2022-2027)
  • Table 152. Hepatitis Drugs Monoclonal Antibody , by Region USD Million (2022-2027)
  • Table 153. Hepatitis Drugs Nucleotide Polymerase/NS5A Inhibitor Combinations , by Region USD Million (2022-2027)
  • Table 154. Hepatitis Drugs HIV NRTIs , by Region USD Million (2022-2027)
  • Table 155. Hepatitis Drugs NS5A Inhibitors , by Region USD Million (2022-2027)
  • Table 156. Hepatitis Drugs Nucleotide Polymerase Inhibitors , by Region USD Million (2022-2027)
  • Table 157. Hepatitis Drugs Others , by Region USD Million (2022-2027)
  • Table 158. Hepatitis Drugs: by Disease Type(USD Million)
  • Table 159. Hepatitis Drugs Hepatitis A , by Region USD Million (2022-2027)
  • Table 160. Hepatitis Drugs Hepatitis B , by Region USD Million (2022-2027)
  • Table 161. Hepatitis Drugs Hepatitis C , by Region USD Million (2022-2027)
  • Table 162. Hepatitis Drugs Others , by Region USD Million (2022-2027)
  • Table 163. Hepatitis Drugs: by Route of Administration(USD Million)
  • Table 164. Hepatitis Drugs Oral , by Region USD Million (2022-2027)
  • Table 165. Hepatitis Drugs Injection , by Region USD Million (2022-2027)
  • Table 166. Hepatitis Drugs: by End-User(USD Million)
  • Table 167. Hepatitis Drugs Hospital Pharmacies , by Region USD Million (2022-2027)
  • Table 168. Hepatitis Drugs Retail Pharmacies , by Region USD Million (2022-2027)
  • Table 169. Hepatitis Drugs Online Pharmacies , by Region USD Million (2022-2027)
  • Table 170. South America Hepatitis Drugs, by Country USD Million (2022-2027)
  • Table 171. South America Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 172. South America Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 173. South America Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 174. South America Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 175. Brazil Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 176. Brazil Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 177. Brazil Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 178. Brazil Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 179. Argentina Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 180. Argentina Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 181. Argentina Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 182. Argentina Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 183. Rest of South America Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 184. Rest of South America Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 185. Rest of South America Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 186. Rest of South America Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 187. Asia Pacific Hepatitis Drugs, by Country USD Million (2022-2027)
  • Table 188. Asia Pacific Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 189. Asia Pacific Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 190. Asia Pacific Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 191. Asia Pacific Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 192. China Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 193. China Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 194. China Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 195. China Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 196. Japan Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 197. Japan Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 198. Japan Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 199. Japan Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 200. India Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 201. India Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 202. India Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 203. India Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 204. South Korea Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 205. South Korea Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 206. South Korea Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 207. South Korea Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 208. Taiwan Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 209. Taiwan Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 210. Taiwan Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 211. Taiwan Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 212. Australia Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 213. Australia Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 214. Australia Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 215. Australia Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 216. Rest of Asia-Pacific Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 217. Rest of Asia-Pacific Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 218. Rest of Asia-Pacific Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 219. Rest of Asia-Pacific Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 220. Europe Hepatitis Drugs, by Country USD Million (2022-2027)
  • Table 221. Europe Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 222. Europe Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 223. Europe Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 224. Europe Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 225. Germany Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 226. Germany Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 227. Germany Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 228. Germany Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 229. France Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 230. France Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 231. France Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 232. France Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 233. Italy Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 234. Italy Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 235. Italy Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 236. Italy Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 237. United Kingdom Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 238. United Kingdom Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 239. United Kingdom Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 240. United Kingdom Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 241. Netherlands Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 242. Netherlands Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 243. Netherlands Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 244. Netherlands Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 245. Rest of Europe Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 246. Rest of Europe Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 247. Rest of Europe Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 248. Rest of Europe Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 249. MEA Hepatitis Drugs, by Country USD Million (2022-2027)
  • Table 250. MEA Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 251. MEA Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 252. MEA Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 253. MEA Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 254. Middle East Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 255. Middle East Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 256. Middle East Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 257. Middle East Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 258. Africa Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 259. Africa Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 260. Africa Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 261. Africa Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 262. North America Hepatitis Drugs, by Country USD Million (2022-2027)
  • Table 263. North America Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 264. North America Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 265. North America Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 266. North America Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 267. United States Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 268. United States Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 269. United States Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 270. United States Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 271. Canada Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 272. Canada Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 273. Canada Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 274. Canada Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 275. Mexico Hepatitis Drugs, by Type USD Million (2022-2027)
  • Table 276. Mexico Hepatitis Drugs, by Disease Type USD Million (2022-2027)
  • Table 277. Mexico Hepatitis Drugs, by Route of Administration USD Million (2022-2027)
  • Table 278. Mexico Hepatitis Drugs, by End-User USD Million (2022-2027)
  • Table 279. Hepatitis Drugs: by Type(USD/Units)
  • Table 280. Research Programs/Design for This Report
  • Table 281. Key Data Information from Secondary Sources
  • Table 282. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hepatitis Drugs: by Type USD Million (2016-2021)
  • Figure 5. Global Hepatitis Drugs: by Disease Type USD Million (2016-2021)
  • Figure 6. Global Hepatitis Drugs: by Route of Administration USD Million (2016-2021)
  • Figure 7. Global Hepatitis Drugs: by End-User USD Million (2016-2021)
  • Figure 8. South America Hepatitis Drugs Share (%), by Country
  • Figure 9. Asia Pacific Hepatitis Drugs Share (%), by Country
  • Figure 10. Europe Hepatitis Drugs Share (%), by Country
  • Figure 11. MEA Hepatitis Drugs Share (%), by Country
  • Figure 12. North America Hepatitis Drugs Share (%), by Country
  • Figure 13. Global Hepatitis Drugs: by Type USD/Units (2016-2021)
  • Figure 14. Global Hepatitis Drugs share by Players 2021 (%)
  • Figure 15. Global Hepatitis Drugs share by Players (Top 3) 2021(%)
  • Figure 16. Global Hepatitis Drugs share by Players (Top 5) 2021(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. F. Hoffmann-La Roche Revenue, Net Income and Gross profit
  • Figure 19. F. Hoffmann-La Roche Revenue: by Geography 2021
  • Figure 20. Gilead Sciences Revenue, Net Income and Gross profit
  • Figure 21. Gilead Sciences Revenue: by Geography 2021
  • Figure 22. GlaxoSmithKline Revenue, Net Income and Gross profit
  • Figure 23. GlaxoSmithKline Revenue: by Geography 2021
  • Figure 24. Johnson & Johnson Revenue, Net Income and Gross profit
  • Figure 25. Johnson & Johnson Revenue: by Geography 2021
  • Figure 26. Merck Revenue, Net Income and Gross profit
  • Figure 27. Merck Revenue: by Geography 2021
  • Figure 28. Novartis Revenue, Net Income and Gross profit
  • Figure 29. Novartis Revenue: by Geography 2021
  • Figure 30. Vertex Pharmaceuticals Revenue, Net Income and Gross profit
  • Figure 31. Vertex Pharmaceuticals Revenue: by Geography 2021
  • Figure 32. Abbvie Revenue, Net Income and Gross profit
  • Figure 33. Abbvie Revenue: by Geography 2021
  • Figure 34. Achillion Pharmaceuticals Revenue, Net Income and Gross profit
  • Figure 35. Achillion Pharmaceuticals Revenue: by Geography 2021
  • Figure 36. Bristol-Myers SquibbMerck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Bristol-Myers SquibbMerck & Co. Inc. (United States) Revenue: by Geography 2021
  • Figure 38. Gilead Sciences Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 39. Gilead Sciences Inc. (United States) Revenue: by Geography 2021
  • Figure 40. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 41. AbbVie Inc. (United States) Revenue: by Geography 2021
  • Figure 42. Bristol Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 43. Bristol Myers Squibb Company (United States) Revenue: by Geography 2021
  • Figure 44. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 45. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2021
  • Figure 46. LAURUS Labs (India) Revenue, Net Income and Gross profit
  • Figure 47. LAURUS Labs (India) Revenue: by Geography 2021
  • Figure 48. Zydus Cadila (India) Revenue, Net Income and Gross profit
  • Figure 49. Zydus Cadila (India) Revenue: by Geography 2021
  • Figure 50. Hetero Healthcare Limited (India) Revenue, Net Income and Gross profit
  • Figure 51. Hetero Healthcare Limited (India) Revenue: by Geography 2021
  • Figure 52. GlaxoSmithKline PLC. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 53. GlaxoSmithKline PLC. (United Kingdom) Revenue: by Geography 2021
  • Figure 54. Cipla Inc. (India) Revenue, Net Income and Gross profit
  • Figure 55. Cipla Inc. (India) Revenue: by Geography 2021
  • Figure 56. Global Hepatitis Drugs: by Type USD Million (2022-2027)
  • Figure 57. Global Hepatitis Drugs: by Disease Type USD Million (2022-2027)
  • Figure 58. Global Hepatitis Drugs: by Route of Administration USD Million (2022-2027)
  • Figure 59. Global Hepatitis Drugs: by End-User USD Million (2022-2027)
  • Figure 60. South America Hepatitis Drugs Share (%), by Country
  • Figure 61. Asia Pacific Hepatitis Drugs Share (%), by Country
  • Figure 62. Europe Hepatitis Drugs Share (%), by Country
  • Figure 63. MEA Hepatitis Drugs Share (%), by Country
  • Figure 64. North America Hepatitis Drugs Share (%), by Country
  • Figure 65. Global Hepatitis Drugs: by Type USD/Units (2022-2027)
Some of the key companies/manufacturers profiled in the report
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Novartis
  • Vertex Pharmaceuticals
  • Abbvie
  • Achillion Pharmaceuticals
  • Bristol-Myers SquibbMerck & Co. Inc. (United States)
  • Gilead Sciences Inc. (United States)
  • AbbVie Inc. (United States)
  • Bristol Myers Squibb Company (United States)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • LAURUS Labs (India)
  • Zydus Cadila (India)
  • Hetero Healthcare Limited (India)
  • GlaxoSmithKline PLC. (United Kingdom)
  • Cipla Inc. (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation